Growth Factor Concentrate (GFC) for the Management of Osteoarthritis of the Knee: A Systematic Review.

Autologous blood Autologous blood-derived biologics GFC Growth factor concentrate Knee osteoarthritis Orthobiologics Ossinext PROMs Patient-reported outcome measures Regenerative medicine

Journal

Indian journal of orthopaedics
ISSN: 0019-5413
Titre abrégé: Indian J Orthop
Pays: Switzerland
ID NLM: 0137736

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 27 03 2024
accepted: 24 04 2024
pmc-release: 09 05 2025
medline: 1 7 2024
pubmed: 1 7 2024
entrez: 1 7 2024
Statut: epublish

Résumé

The knee is the most commonly affected joint in osteoarthritis (OA), affecting millions of people worldwide. Knee OA significantly impacts the activities of daily living (ADL) along with affecting overall quality of life of patients (QoL), thereby leading to substantial socio-economic burden. Conservative therapies are prioritized, resorting to surgery only when needed. However, these traditional approaches have limitations. Regenerative medicine, involving the use of orthobiologics, including autologous peripheral blood-derived orthobiologics such as growth factor concentrate (GFC), has evolved and shown potential for managing knee OA. The primary goal of this review is to summarize the results of in vitro, preclinical and clinical studies involving GFC for the management of knee OA. Multiple databases (PubMed, Scopus, Google Scholar, Web of Science and Embase) were searched applying terms for the intervention 'GFC' and treatment 'knee OA' for the studies published in the English language to March 10, 2024. Only three clinical studies met our pre-defined criteria and were included in this review. Intra-articular administration of GFC is safe and potentially efficacious to manage OA of the knee. More, adequately powered, multi-center, prospective, RCTs are warranted to demonstrate the long-term effectiveness of GFC in patients suffering from mild-to-moderate knee OA and to justify its routine clinical use. Further studies evaluating the efficacy of GFC compared to other orthobiologics are also required to allow physicians/surgeons to choose the optimal orthobiologic for the treatment of OA of the knee.

Identifiants

pubmed: 38948375
doi: 10.1007/s43465-024-01172-w
pii: 1172
pmc: PMC11208381
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

829-834

Informations de copyright

© Indian Orthopaedics Association 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Déclaration de conflit d'intérêts

Conflict of interestThe authors declare that they have no competing interests.

Auteurs

Ashim Gupta (A)

Future Biologics, Lawrenceville, GA 30043 USA.
Regenerative Orthopaedics, Noida, 201301 India.
South Texas Orthopaedic Research Institute (STORI Inc.), Laredo, TX 78045 USA.
BioIntegrate, Lawrenceville, GA 30043 USA.

Nicola Maffulli (N)

Department of Trauma and Orthopaedic Surgery, Faculty of Medicine and Psychology, University La Sapienza, 00185 Rome, Italy.
Centre for Sports and Exercise Medicine, Barts and the London School of Medicine and Dentistry, Mile End Hospital, Queen Mary University of London, London, E1 4DG UK.
School of Pharmacy and Bioengineering, Keele University School of Medicine, Stoke On Trent, ST4 7QB UK.

Classifications MeSH